Medicine and Dentistry
Randomized Controlled Trial
100%
Attention Deficit Disorder
50%
Anti-Citrullinated Protein Antibody
50%
Cannabinoid
50%
Personality Disorder
50%
Rheumatoid Arthritis
50%
Inflammatory Arthritis
50%
Disease Modifying Antirheumatic Drug
50%
Structured Clinical Interview for DSM Disorders
25%
Placebo
25%
Cannabis
15%
Methotrexate
12%
Nabiximols
10%
Mental Instability
10%
Adverse Event
10%
Antirheumatic Agent
9%
Clinical Population
8%
Health Outcomes
8%
Sensitivity and Specificity
8%
Clinician
8%
Prednisolone
6%
Cyclosporine
6%
Monotherapy
6%
DAS28
6%
Odds Ratio
6%
Endocannabinoid System
5%
Psychiatrist
5%
Self-Medication
5%
Hyperactivity
5%
Cognitive Defect
5%
Muscle Spasm
5%
Impulsiveness
5%
Cardiovascular System
5%
Cannabis Use
5%
Epileptic Seizure
5%
Medicine
5%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Cannabinoid
50%
Attention Deficit Disorder
50%
Rheumatoid Arthritis
50%
Inflammatory Arthritis
50%
Cyclic Citrullinated Peptide Antibody
50%
Personality Disorder
50%
Disease Modifying Antirheumatic Drug
50%
Placebo
25%
DSM-IV
25%
Cannabis
20%
Methotrexate
12%
Adverse Event
10%
Mental Instability
10%
Nabiximols
10%
Antirheumatic Agent
9%
Ciclosporin
6%
Prednisolone
6%
Monotherapy
6%
Hyperactivity
5%
Cognitive Defect
5%
Self-Medication
5%
Muscle Spasm
5%
Endocannabinoid System
5%
Nursing and Health Professions
Inflammatory Arthritis
50%
Rheumatoid Arthritis
50%
Disease Modifying Antirheumatic Drug
50%
Cyclic Citrullinated Peptide Antibody
50%
Attention Deficit Disorder
50%
Placebo
25%
Cannabis
20%
Methotrexate
12%
Adverse Event
10%
Nabiximols
10%
Mental Instability
10%
Confidence Interval
9%
Antirheumatic Agent
9%
Ciclosporin
6%
Prednisolone
6%
Monotherapy
6%
DAS28
6%
Odds Ratio
6%
Endocannabinoid
5%
Hyperactivity
5%
Muscle Spasm
5%
Experimental Medicine
5%
Psychiatrist
5%
Cognitive Defect
5%
Self Medication
5%
